Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats parenchymal neurocysticercosis due to active lesions caused by larval forms of the…. Sold as Albenza. Every FDA application for this active ingredient: 1 branded and 9 generic.
As of Nov 14, 2026, FDA lists 10 applications for Albendazole (sold as Albenza), first approved Jun 11, 1996, with 0 new uses approved and 0 published complete response letters.
First approved: Jun 11, 1996
Applications: 10
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $3.3M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Albendazole
Part D
$3.3M
-46%
10,259
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
ALBENDAZOLE 200 MG TABLET: $4.13 per unitGeneric · -31% in a year
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Impax Labs Inc
Strides Pharma
Zydus Pharms
Alembic